MARKET

FGEN

FGEN

Fibrogen Inc
NASDAQ
0.4393
+0.0122
+2.86%
After Hours: 0.4400 +0.0007 +0.16% 19:58 03/14 EDT
OPEN
0.4210
PREV CLOSE
0.4271
HIGH
0.4651
LOW
0.4210
VOLUME
1.22M
TURNOVER
--
52 WEEK HIGH
2.800
52 WEEK LOW
0.1800
MARKET CAP
44.27M
P/E (TTM)
-0.3574
1D
5D
1M
3M
1Y
5Y
1D
Catalyst Watch: Nvidia event could revive animal spirits, Fed meeting, and Nike earnings
Seeking Alpha · 1d ago
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 2d ago
Weekly Report: what happened at FGEN last week (0303-0307)?
Weekly Report · 6d ago
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results
Barchart · 03/03 15:45
Weekly Report: what happened at FGEN last week (0224-0228)?
Weekly Report · 03/03 09:08
Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates
NASDAQ · 02/27 12:10
FIBROGEN INC - ENTERED ATM EQUITY OFFERING SALES AGREEMENT RELATING TO SALE FROM TIME TO TIME OF SHARES OF COMMON STOCK
Reuters · 02/24 22:22
FIBROGEN- MAY OFFER, SELL SHARES OF COMMON STOCK FOR OFFERING PRICE OF UP TO $30.0 MLN FROM TIME TO TIME THROUGH BOFA
Reuters · 02/24 22:22
More
About FGEN
More
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.
Recently
Symbol
Price
%Change

Webull offers FibroGen Inc stock information, including NASDAQ: FGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FGEN stock methods without spending real money on the virtual paper trading platform.